Dosimetric comparison of simultaneous integrated boost versus concomitant electron boost in radiotherapy treatment of breast cancer

2017 ◽  
Vol 16 (3) ◽  
pp. 334-341 ◽  
Author(s):  
C. Y. Yuen ◽  
W. L. Au ◽  
W. L. Chan ◽  
Y. T. Yiu ◽  
Y. Y. Law ◽  
...  
Keyword(s):  
Target Volume ◽  
Simultaneous Integrated Boost ◽  
Skin Dose ◽  
Computed Tomographic ◽  
Heart Dose ◽  
Adequate Dose ◽  
Sequential Boost ◽  
Significant Difference ◽  
Integrated Boost ◽  
Electron Boost

AbstractBackgroundThe aim of this study was to compare the dosimetric parameters and effects of simultaneous integrated boost (SIB) and traditional sequential electron boost, after helical tomotherapy, because of the lack of studies in this field in the current literature.MethodsComputed tomographic data of 14 patients who received SIB in 2012–2015 were collected from Hong Kong Sanatorium & Hospital. New tomotherapy with SIB plans and tomotherapy with sequential boost plans were generated for each patient, and results were compared.ResultsConformation number, mean dose, dose received by 95% volume (both sides), ipsilateral lung volume receiving 20 Gy (V20) and skin dose (right side) were found to be significantly better for SIB (p<0·05), however coverage index and gross target volume dose showed no significant difference, and heart dose was significantly higher for SIB on the right side.ConclusionTomotherapy with SIB may be able to offer less organ at risk dose (except for the heart), while maintaining the ability to deliver adequate dose coverage.

scholarly journals Simultaneous Integrated Boost Intensity-Modulated Radiotherapy for Locally Advanced Drug-Resistant Gastrointestinal Stromal Tumors: A Feasibility Study

2020 ◽  
Vol 10 ◽  
Author(s):  
Longhao Li ◽  
Xin Yi ◽  
Haixia Cui ◽  
Xuemei Zhao ◽  
Jun Dang ◽  
...  
Keyword(s):  
Tumor Size ◽  
Gastrointestinal Stromal Tumors ◽  
Locally Advanced ◽  
Target Volume ◽  
Simultaneous Integrated Boost ◽  
Drug Resistant ◽  
Stromal Tumors ◽  
Intensity Modulated ◽  
Significant Difference ◽  
Integrated Boost

BackgroundAs an emerging clinical problem, locally advanced drug-resistant gastrointestinal stromal tumors (LADRGISTs) has relatively few therapeutic schemes. Although radiotherapy is not often considered for GISTs, it could be a valuable contributing modality. The aim of our study is to explore a safe and effective radiation regimen for LADR-GISTs.MethodsThree patients with LADR-GISTs were treated with simultaneous integrated boost intensity-modulated radiation therapy (SIB-IMRT) plans. In the SIB-IMRT plans, gross target volume (GTV) was divided into GTV-outer, GTV-mid, and GTV-center. And the prescribed dose of planning gross target volume (PGTV) and GTV-outer were both set to 50.4 Gy in 28 fractions. GTV-mid and GTV-center were simultaneously boosted to 60–62 Gy and 62–64 Gy respectively. For comparison purposes, conventional IMRT (Con-IMRT) plans with uniform dose distribution were generated for same optimization objectives without a dose boost to GTV-mid and GTV-center. All plans were optimized to make sure that deliver at least 95% of the prescription dose was delivered to PGTV. Isodose distribution, dose profiles, conformity indexes (CIs), monitor units (MUs), and dose volume histogram (DVH) was evaluated for each individual patient. After the three patients were treated with SIB-IMRT plans, the relative changes in the tumor size and CT values by CT scanning were also tracked.ResultsCompared with Con-IMRT plans, SIB-IMRT plans saw a significant increase from D95 to D2 of the GTV. With steeper dose gradients in the dose profiles, SIB-IMRT plans had GTV-mid and GTV-center accumulated with higher dose mainly by delivering extra 93 MUs in average. However, there was no significant difference in CIs and organs at risks (OARs) DVH. The relative changes in tumor size and CT values of the three patients in follow up were up to the Choi criteria and the three patients were all assessed as partial response.ConclusionsThe proposed SIB-IMRT may be a potential technique for achieving objective response and prolonging survival of selected GISTs patients.

scholarly journals Radiooncological View on Therapy Outcome after Multidisciplinary Treatment of Sinonasal Tumors

Cancers ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 2364
Author(s):  
Olena Klymenko ◽  
Anna Maria Stefanie Buchberger ◽  
Barbara Wollenberg ◽  
Klaus-Dietrich Wolff ◽  
Victoria Kehl ◽  
...  
Keyword(s):  
Tumor Volume ◽  
Multidisciplinary Treatment ◽  
Treatment Strategies ◽  
Entire Group ◽  
Sinonasal Carcinoma ◽  
Volume Delineation ◽  
Sequential Boost ◽  
Significant Difference ◽  
Integrated Boost ◽  
Primary Focus

Purpose: We report the outcome of a mono-institutional retrospective study of sinonasal carcinoma with the primary focus on GTV (gross tumor volume) and the effect of radiotherapy. Methods: 53 patients with sinonasal carcinoma and that of the nasal cavity, paranasal sinus or both except lymphoma were included. All patients were treated between 1999 and 2017. For tumor volume delineation, all pre-therapeutic images were fused to the planning CT (computed tomography). Results: The median follow-up was 17 months [0.3–60], the median age 60 years, 35 males and 18 females were included. Squamous cell carcinoma (SCC) (60.4%) was the predominant histology, followed by adenocarcinoma (15.1%). The mean composite OS (overall survival) time was 33.3 ± 3.5 months. There was no significant difference in the 5 y composite OS between tumor localization or radiotherapy setting. The simultaneous integrated boost concept showed a trend towards improving five-year composite OS compared to the sequential boost concept. The only factor with a significant impact on the 5 y composite OS rate was the pre-therapeutic GTV (cutoff 75 cm3; p = 0.033). The GTV ≥ 100 cm3 has no effect on the 5 y composite OS rate for SCC. Conclusions: The pre-therapeutic GTV is a prognostic factor for five-year composite OS for the entire group of patients with sinonasal tumors, influencing the outcome after completion of all treatment strategies. The GTV seems to not influence five-year composite OS in SCC. For this rare tumor entity, an intensive, multidisciplinary discussion is essential to finding the best treatment option for the patient.

scholarly journals Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study

2018 ◽  
Vol 13 (1) ◽  
Author(s):  
Pierfrancesco Franco ◽  
Berardino De Bari ◽  
Francesca Arcadipane ◽  
Alexis Lepinoy ◽  
Manuela Ceccarelli ◽  
...  
Keyword(s):  
Observational Study ◽  
Cancer Patients ◽  
Anal Cancer ◽  
Simultaneous Integrated Boost ◽  
Retrospective Observational Study ◽  
Sequential Boost ◽  
Integrated Boost

Dosimetric and radiobiological comparison of external beam radiotherapy using simultaneous integrated boost technique for esophageal cancer in different location.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e15505-e15505
Author(s):  
Lu Wang ◽  
Jinming Yu
Keyword(s):  
Esophageal Cancer ◽  
External Beam Radiotherapy ◽  
Intensity Modulated Radiotherapy ◽  
Target Volume ◽  
Simultaneous Integrated Boost ◽  
Conformity Index ◽  
Tumor Control ◽  
Tumor Control Probability ◽  
Integrated Boost ◽  
Treatment Plans

e15505 Background: Based on dosimetry and radiobiology to compare treatment plans for esophageal cancer (EC) in different location using intensity modulated radiotherapy (IMRT), volumetric modulated arc radiotherapy (VMAT) and helical tomotherapy(HT) with simultaneous integrated boost (SIB) technique. Methods: A total of 20 patients including 5 cases respectively located in the cervix, upper, middle and lower thorax were generated for IMRT, VMAT and HT plans. The dose volume histogram statistics, conformity index (CI), homogeneity index (HI), tumor control probability (TCP) and normal tissues control probability (NTCP) were analyzed to evaluate treatment plans. Results: HT showed significantly improvement over IMRT and VMAT in terms of CI(0.93±0.03), HI(0.07±0.03) and TCP(88.08±0.82%) in cervical EC(p<0.05). IMRT greatly developed TCP(88.29±1.79%;85.11±0.79%), and offered superior CIs (0.87±0.04;0.90±0.01) and HIs(0.10±0.01; 0.06±0.01) compared with VMAT and HT in upper and middle thoracic EC(p<0.05). Meanwhile, the V30(33.30±6.49%), mean dose (2559.00±219.64cGy) and NTCP(0.50±0.61%) of heart for IMRT were significantly reduced than other two techniques in middle thoracic EC. Patients with lower thoracic EC yielded the similar CIs and HIs(all p>0.05) for the 3 techniques, but VMAT showed the lowest NTCP of lungs (0.01±0.01%) with improved TCP (84.84±1.13%). Conclusions: HT was a good option with little lung and heart involvement as it achieved superior dose conformality and uniformity. IMRT was a perfect strategy with large thoracic involvement. It significantly improved tumor local control and reduced heart dose and complications with acceptable dose to lungs. VMAT was preferred with a smaller target volume but surrounded by more heart and less lungs. Individually choosing optimal technique for EC in different location will be warranted.

Heart dose reduction in breast cancer treatment with simultaneous integrated boost

2015 ◽  
Vol 191 (9) ◽  
pp. 734-741 ◽  
Author(s):  
Vincent Jöst ◽  
Matthias Kretschmer ◽  
Marcello Sabatino ◽  
Florian Würschmidt ◽  
Jörg Dahle ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Dose Reduction ◽  
Breast Cancer Treatment ◽  
Simultaneous Integrated Boost ◽  
Heart Dose ◽  
Integrated Boost
Sign in / Sign up

Export Citation Format

Share Document